Galenghui October 15th | HaiChuang Pharmaceuticals (688302.SH) announced that it has received the Drug Clinical Trial Approval Notice approved and issued by the China National Medical Products Administration Drug Evaluation Center, approving the HP568 tablets for the clinical trial of treating late-stage breast cancer with Estrogen Receptor (ER) positive and Human Epidermal Growth Factor Receptor 2 (HER2) negative (ER+/HER2- late-stage breast cancer). As of the date of this announcement, there are no similar PROTAC products approved for marketing domestically or internationally.
海创药业(688302.SH)：口服PROTAC药物HP568片用于治疗ER+/HER2-晚期乳腺癌的临床试验获得药物临床试验批准通知书
Haisco Pharmaceutical Co., Ltd. (688302.SH): The oral PROTAC drug HP568 tablets for the clinical trial of ER+/HER2- advanced breast cancer obtained the Drug Clinical Trial Approval Letter.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated